Clinical trial
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in…
NCT00215644 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00215644 |
|---|---|
| Title | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer |
| Official title | Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma |
| Acronym | MATRIX EG |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | Matuzumab, Epirubicin, Cisplatin, Capecitabine |
| Enrollment | 72 |
| Start date | Aug 31, 2005 |
| Primary completion | Jul 31, 2008 |
| Completion | Aug 31, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 2, 2018 |
| Countries | Germany, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: